dr lal pathlabs
Jump to
147 Results Found
  • Dr Lal PathLabs' Q2 net profit rises 6%, revenue up 18% YoY Nov 06, 2020 03:20 PM IST

    Dr Lal PathLabs' Q2 net profit rises 6%, revenue up 18% YoY

    Consolidated revenue for the said quarter came at Rs 431.9 crore, up 18 percent YoY from Rs 365.6 crore in the corresponding quarter of the previous financial year.

  • Diagnostic firms ride the COVID-19 wave, retention of business gains key Oct 14, 2020 10:22 AM IST

    Diagnostic firms ride the COVID-19 wave, retention of business gains key

    Diagnostic firms such as Dr Lal PathLabs, Thyrocare Technologies and Metropolis Healthcare rebound as COVID-19 related tests drive business growth. While non COVID-19 business is showing signs of normalisation, sustainability of recovery is key

  • Dr Lal PathLabs exposed data of millions of patients, including COVID-19 test results: Report Oct 09, 2020 08:44 PM IST

    Dr Lal PathLabs exposed data of millions of patients, including COVID-19 test results: Report

    The data included patients’ booking details such as their name, address, phone number, email id, payment details, digital signature, and also the type of medical tests they had taken.

  • Hold Dr. Lal PathLabs; target of Rs 1995: Geojit Aug 09, 2020 09:02 AM IST

    Hold Dr. Lal PathLabs; target of Rs 1995: Geojit

    Geojit recommended recommended hold rating on Dr. Lal PathLabs with a target price of Rs 1995 in its research report dated August 06, 2020.

  • Sell Dr. Lal PathLabs; target of Rs 1006: Prabhudas Lilladher Aug 08, 2020 12:34 PM IST

    Sell Dr. Lal PathLabs; target of Rs 1006: Prabhudas Lilladher

    Prabhudas Lilladher is bearish on Dr. Lal PathLabs has recommended sell rating on the stock with a target price of Rs 1006 in its research report dated August 03, 2020.

  • Dr Lal PathLabs Q1 profit falls 52% to Rs 28.4 crore Jul 31, 2020 03:06 PM IST

    Dr Lal PathLabs Q1 profit falls 52% to Rs 28.4 crore

    Its revenue was down 20.6% at Rs 266 crore against Rs 335.2 crore.

  • Dr Lal PathLabs shares extend gains into 3rd day; analysts positive on firm's long term story Jul 15, 2020 02:02 PM IST

    Dr Lal PathLabs shares extend gains into 3rd day; analysts positive on firm's long term story

    Despite the turmoil caused by COVID-19, the stock has been gaining significantly in the calendar year 2020 so far. The stock has gained 27 percent as of July 14 close on BSE against a 13 percent fall in benchmark Sensex.

  • Outlook for diagnostics industry favourable for growth: Dr Lal PathLabs Jul 07, 2020 04:25 PM IST

    Outlook for diagnostics industry favourable for growth: Dr Lal PathLabs

    The company, in its Annual Report for 2019-20, stated that instances and situations like the COVID-19 outbreak further boost the importance of diagnostics as an integral part of healthcare system.

  • Sell Dr. Lal PathLabs; target of Rs 895: Prabhudas Lilladher May 19, 2020 11:05 AM IST

    Sell Dr. Lal PathLabs; target of Rs 895: Prabhudas Lilladher

    Prabhudas Lilladher is bearish on Dr. Lal PathLabs has recommended sell rating on the stock with a target price of Rs 895 in its research report dated May 19, 2020.

  • Thyrocare Tech, Dr Lal PathLabs rise 9% as govt allow private lab to do coronavirus testing Mar 18, 2020 11:24 AM IST

    Thyrocare Tech, Dr Lal PathLabs rise 9% as govt allow private lab to do coronavirus testing

    The total number of coronavirus cases in India rose to 147, with 10 fresh cases reported from various parts of the country.

  • Dr Lal PathLabs shares fall 3% despite a decent Q3 show Feb 04, 2020 11:32 AM IST

    Dr Lal PathLabs shares fall 3% despite a decent Q3 show

    The company reported a 19.08 percent year-on-year increase in consolidated net profit at Rs 54.9 crore for the quarter ended December 31.

  • Dr Lal PathLabs Q3 net profit up 19% to Rs 54.9cr Feb 03, 2020 04:25 PM IST

    Dr Lal PathLabs Q3 net profit up 19% to Rs 54.9cr

    The company had posted a net profit of Rs 46.1 crore in the corresponding period of the previous fiscal, Dr Lal PathLabs said in a filing to the BSE.

  • Dr Lal PathLab Standalone December 2019 Net Sales at Rs 310.40 crore, up 9.76% Y-o-Y Feb 03, 2020 03:35 PM IST

    Dr Lal PathLab Standalone December 2019 Net Sales at Rs 310.40 crore, up 9.76% Y-o-Y

  • Dr Lal Pathlabs Q2 PAT seen up 48.8% YoY to Rs. 84.8 cr: Kotak Oct 11, 2019 03:26 PM IST

    Dr Lal Pathlabs Q2 PAT seen up 48.8% YoY to Rs. 84.8 cr: Kotak

    Net Sales are expected to increase by 14.8 percent Y-o-Y (up 8.7 percent Q-o-Q) to Rs. 364.5 crore, according to Kotak.

  • 'Equity market selloff has boosted demand for Gold and Silver' Sep 04, 2019 11:09 AM IST

    'Equity market selloff has boosted demand for Gold and Silver'

    The overall demand for Gold and silver investments have also increased in the current period to an all-time high, due to volatile Indian equity markets and further concerns about the health of the Indian economy.

  • Accumulate Dr. Lal PathLabs; target of Rs 1120: Prabhudas Lilladher Aug 14, 2019 04:30 PM IST

    Accumulate Dr. Lal PathLabs; target of Rs 1120: Prabhudas Lilladher

    Prabhudas Lilladher recommended accumulate rating on Dr. Lal PathLabs with a target price of Rs 1120 in its research report dated August 14, 2019.

  • Dr Lal Pathlabs Q1 PAT seen up 17.6% YoY to Rs. 58.1 cr: Kotak Jul 15, 2019 02:59 PM IST

    Dr Lal Pathlabs Q1 PAT seen up 17.6% YoY to Rs. 58.1 cr: Kotak

    Net Sales are expected to increase by 14 percent Y-o-Y (up 10.7 percent Q-o-Q) to Rs. 333.2 crore, according to Kotak.

  • Dr. Lal PathLabs Q1 PAT seen up 5.5% YoY to Rs. 52.1 cr: Prabhudas Lilladher Jul 12, 2019 04:45 PM IST

    Dr. Lal PathLabs Q1 PAT seen up 5.5% YoY to Rs. 52.1 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 15 percent Y-o-Y (up 11.6 percent Q-o-Q) to Rs. 336.1 crore, according to Prabhudas Lilladher.

  • Dr Lal PathLab Standalone March 2019 Net Sales at Rs 292.00 crore, up 12.96% Y-o-Y May 17, 2019 04:00 PM IST

    Dr Lal PathLab Standalone March 2019 Net Sales at Rs 292.00 crore, up 12.96% Y-o-Y

  • Dr Lal Pathlabs Q4 PAT seen up 28.3% YoY to Rs. 51.4 cr: Kotak Apr 17, 2019 03:06 PM IST

    Dr Lal Pathlabs Q4 PAT seen up 28.3% YoY to Rs. 51.4 cr: Kotak

    Net Sales are expected to increase by 15.3 percent Y-o-Y (up 5.2 percent Q-o-Q) to Rs. 307.7 crore, according to Kotak.

  • Dr. Lal Pathlabs Q4 PAT seen up 26.2% YoY to Rs. 50.6 cr: Prabhudas Lilladher Apr 12, 2019 12:56 PM IST

    Dr. Lal Pathlabs Q4 PAT seen up 26.2% YoY to Rs. 50.6 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 30.2 percent Y-o-Y (up 18.8 percent Q-o-Q) to Rs. 347.4 crore, according to Prabhudas Lilladher.

  • 75 BSE 500 cos can pay Rs 1.1 lakh crore more to shareholders: Report Apr 11, 2019 08:05 PM IST

    75 BSE 500 cos can pay Rs 1.1 lakh crore more to shareholders: Report

    The 75 companies can return a median of 49 percent of their total cash and cash equivalents to their shareholders.

  • Dr Lal PathLabs gains 3% on acquisition of Bawankar Pathology Apr 02, 2019 11:01 AM IST

    Dr Lal PathLabs gains 3% on acquisition of Bawankar Pathology

    At 1015 hrs, Dr Lal PathLabs was quoting Rs 1076, up 2.81 percent on the BSE.

  • Accumulate Dr. Lal PathLabs; target of Rs 1070: Prabhudas Lilladher Feb 18, 2019 02:11 PM IST

    Accumulate Dr. Lal PathLabs; target of Rs 1070: Prabhudas Lilladher

    Prabhudas Lilladher recommended accumulate rating on Dr. Lal PathLabs with a target price of Rs 1070 in its research report dated February 11, 2019.

  • Dr Lal PathLab Standalone December 2018 Net Sales at Rs 282.80 crore, up 11.16% Y-o-Y Feb 11, 2019 10:48 AM IST

    Dr Lal PathLab Standalone December 2018 Net Sales at Rs 282.80 crore, up 11.16% Y-o-Y

Sections